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METHODS
Midodrine Tolerance Test 
Three months prior to flight, a single 10 mg dose of midodrine was administered 
orally and the subject was monitored every 15 minutes for brachial artery 
pressure and heart rate as they went about their normal activities for 4 hours.
Preflight tilt test
Orthostatic responses were determined ten days before flight (L-10). Blood 
pressure, EKG and stroke volume were acquired during five minutes of supine 
posture followed by up to ten minutes of 80° head-up tilt.  Cardiac output, heart 
rate and total peripheral resistance were calculated offline.  
Phase I
Six veteran astronauts ingested 10 mg midodrine approximately two hours after 
landing.  One hour after this, orthostatic responses were determined using the 
exact same protocol as L-10.
Phase II
Ten healthy astronauts (7 short duration and 3 long duration) were recruited to 
take 10 mg of midodrine inflight (near TIG) before reentry.  Orthostatic 
responses, similar to those on L-10, were measured immediately upon landing 
in the CTV.  
HYPOTHESIS
Midodrine will reduce the incidence of 
orthostatic hypotension on landing day without 
significant side effects.
ABSTRACT
One possible mechanism for post-spaceflight orthostatic hypotension, which affects 
approximately 30% of astronauts after short duration shuttle missions, is 
inadequate norepinephrine release during upright posture.  We performed a two 
phased study to determine the effectiveness of an α1-adrenergic agonist, midodrine, 
as a countermeasure to post-spaceflight orthostatic hypotension.  The first phase of 
the study examined the landing day orthostatic responses of six veteran astronauts 
after oral midodrine (10 mg) administered on the ground within approximately two 
hours of wheel stop.  One female crewmember exhibited orthostatic hypotension in 
a previous flight but not after midodrine.  Five male crewmembers, who did not 
exhibit orthostatic hypotension during previous flights, also did not show signs of 
orthostatic hypotension after midodrine.  Additionally, phase one showed that 
midodrine did not cause hypertension in these crewmembers.  In the second phase 
of this study, midodrine is ingested inflight (near time of ignition, TIG) and 
orthostatic responses are determined immediately upon landing via an 80° head-up 
tilt test performed on the crew transport vehicle (CTV).  Four of ten crewmembers 
have completed phase two of this study.  Two crewmembers completed the landing 
day tilt tests, while two tests were ended early due to presyncopal symptoms.  All 
subjects had decreased landing day stroke volumes and increased heart rates 
compared to preflight.  Midodrine appears to have increased total peripheral 
resistance in one crewmember who was able to complete the landing day tilt test.  
The effectiveness of midodrine as a countermeasure to immediate post-spaceflight 
orthostatic hypotension has yet to be determined; interpretation is made more 
difficult due to low subject number and the lack of control subjects on the CTV. 
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Midodrine was chosen as an investigational 
countermeasure because:
• It acts in place of norepinephrine on the blood 
vessels. 
• It does not stimulate the central nervous system.
• It does not stimulate the heart directly.   
• Its peak effect is at one hour, so it can be taken at 
Time of Ignition (TIG).           
CONCLUSIONS
• Midodrine had no untoward landing day effects on 
crewmembers that were not susceptible to post-spaceflight 
orthostatic hypotension.  
• Although two crewmembers developed presyncopal 
symptoms during landing day tilt tests, hemodynamic responses to
orthostatic stress appear to be similar whether midodrine was 
ingested on the ground or in orbit.  
• The effectiveness of midodrine as a countermeasure to 
immediate post-spaceflight orthostatic hypotension has yet to be 
determined; interpretation is difficult due to low subject number 
and lack of control subjects on the CTV.  
INTRODUCTION
• Many astronauts experience orthostatic 
hypotension and presyncope upon return to Earth.
• A number of physical and pharmacological 
countermeasures have been tried to counteract 
these problems, unfortunately none have been 
entirely successful. 
• We recently identified a contributory 
mechanism for post-spaceflight orthostatic 
hypotension:  Presyncopal astronauts had smaller
pressor responses to phenylephrine, and did not 
release sufficient norepinephrine during postflight tilt 
tests to maintain standing blood pressure.
• Enhancement of adrenergic response with an 
alpha-1 adrenergic agonist (midodrine) might prevent 
orthostatic intolerance.
RESULTS
PHASE I
• A single, 10 mg oral dose of midodrine did not cause any untoward 
hemodynamic effects on landing day in five male, non-presyncopal subjects, 
and prevented presyncope in one female subject.  
PHASE II
• Four of ten subjects completed to date.  One subject withdrew due to 
unpleasant side effects during tolerance test.
• Two subjects developed presyncopal symptoms on landing day.  
• Although two subjects were presyncopal, hemodynamic responses 
onboard the CTV after midodrine was ingested inflight were similar to those 
from Phase I.
• Results are confounded by poorly controlled environmental variables 
on the CTV (temperature, motion, sound, etc).   
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Figure 2: Hemodynamic responses to midodrine ingestion before and after spaceflight.  Orthostatic 
testing occurred approximately one hour after midodrine ingestion.  Midodrine given 2 hours after 
landing, Phase I (left) and at TIG during Phase II (right).   
Figure 1: Crew Transport Vehicle 
(CTV) at Kennedy Space Center  
(above) and Tilt Test on CTV 
(left).     
PHASE I PHASE II
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